Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL

• DOI: 10.1182/bloodadvances.2024014790
• Publication Date: 2025-03-19T18:58:50Z
• Authors: Rexhep Durmo; Stephane Chauvie; Federico Fallanca; Fabrizio Bergesio; Antonio Pinto; Ilaria Del Giudice; Marta Coscia; Paolo Corradini; Emanuele Angelucci; Patrizia Tosi; Roberto Freilone; Filippo Ballerini; Alessia Bari; Domenico Pastore; Pier Luigi Luigi ...; Silvia Anna Maria...; Leonardo Flenghi; Arcangelo Liso; Jacopo Olivieri; Luigi Marcheselli; Michele Merli; Annibale Versari; Luca Guerra; Stefano Luminari
• Keywords: Follicular lymphoma; Post-hoc analysis

We analysed interim metabolic response (iPET) in a subset of Follicular Lymphoma (FL) patients enrolled the randomized FOLL12 trial. Grade 1-3a FL with an iPET performed between cycles 4 and 5 first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for definition Deauville Score (DS) considered positive DS4-5. Overall 123 out 211 available central review. Of these, 43% older than 60, 33% high-risk FLIPI2, 47% received R-Bendamustine as induction regimen. showed complete (CMR) 83% cases. CMR at end therapy (eoiPET) was confirmed 91% iPET-negative patients. The 5-year PFS 70% (95% CI: 60-78%) 34% iPET-positive 15-55%) cases (p<0.01). In multivariate analysis, iPET+ independent prognostic factor (HR 2.82, 95% 1.47-5.42). Combining eoiPET, 3-year 78% both negative reduced risk progression compared double-positive double iPET/eoiPET OS 96% 89-98%) 85% DS 4-5 61-95%), HR 5.74 1.65-20, p=0.006). Our results confirm that treated standard ICT is strong factor. Assessment early may defining novel generation response-adapted trials FL. NCT02063685